Neuroblastoma screening: arguments from retrospective analysis of three German neuroblastoma trials.
Standard
Neuroblastoma screening: arguments from retrospective analysis of three German neuroblastoma trials. / Berthold, F; Hunneman, D H; Käser, H; Harms, D; Bertram, U; Erttmann, Rudolf; Schilling, F H; Treuner, J; Zieschang, J.
In: J PEDIAT HEMATOL ONC, Vol. 13, No. 1, 1, 1991, p. 8-13.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neuroblastoma screening: arguments from retrospective analysis of three German neuroblastoma trials.
AU - Berthold, F
AU - Hunneman, D H
AU - Käser, H
AU - Harms, D
AU - Bertram, U
AU - Erttmann, Rudolf
AU - Schilling, F H
AU - Treuner, J
AU - Zieschang, J
PY - 1991
Y1 - 1991
N2 - The justification for a neuroblastoma screening program has been discussed controversially. The analysis of 701 patients of the German neuroblastoma trials NB 79, 82, and 85 provides additional information on this subject. The basis of our investigation was the good prognosis of stage I and II patients (92% survival 5-10 years after diagnosis) compared with 66% in stage III and 11% in metastatic disease. The correlation of age and stage (p less than 0.0001), a median progression time of 14.6 months (range 3.4-33.5 mo) from localized to metastatic disease as observed in 18 patients, the high incidence of asymptomatic diseases in stages I (49%) and II (30%) patients and the cost-benefit estimation arguments in favor of a screening program. The key problem for the lab part is the lower incidence of abnormal catecholamine metabolite excretion in stage I and II patients. The origin of 89% of metastatic disease from intraabdominal sites suggests that ultrasonography may be of additional value.
AB - The justification for a neuroblastoma screening program has been discussed controversially. The analysis of 701 patients of the German neuroblastoma trials NB 79, 82, and 85 provides additional information on this subject. The basis of our investigation was the good prognosis of stage I and II patients (92% survival 5-10 years after diagnosis) compared with 66% in stage III and 11% in metastatic disease. The correlation of age and stage (p less than 0.0001), a median progression time of 14.6 months (range 3.4-33.5 mo) from localized to metastatic disease as observed in 18 patients, the high incidence of asymptomatic diseases in stages I (49%) and II (30%) patients and the cost-benefit estimation arguments in favor of a screening program. The key problem for the lab part is the lower incidence of abnormal catecholamine metabolite excretion in stage I and II patients. The origin of 89% of metastatic disease from intraabdominal sites suggests that ultrasonography may be of additional value.
M3 - SCORING: Zeitschriftenaufsatz
VL - 13
SP - 8
EP - 13
JO - J PEDIAT HEMATOL ONC
JF - J PEDIAT HEMATOL ONC
SN - 1077-4114
IS - 1
M1 - 1
ER -
